Does Cystatin C predict diabetes according to glycosylated hemoglobin levels in Korean patients?
Cystatin C is discussed as a potential predictor for diabetes based on HbA1c levels in Korean patients, highlighting its utility beyond renal function assessment.
Cystatin C is entirely filtered by the kidney glomerulus and metabolized by the proximal tubule, and it is mainly used as a biomarker of renal function. It was first proposed by Anders Grubb as a potential alternative to be used as a glomerular filtration rate (GFR) that could overcome the known limitations of serum creatinine 1, and has been investigated for about 30 years. Cystatin C is less influenced by demographic characteristics such age, gender, race, muscle mass, heath status, and drugs than creatinine 2. Most studies have shown the associations of cystatin C and creatinine with longitudinally adverse outcomes of renal disease such as end-stage renal disease, cardiovascular disease (CVD), heart failure, and death 3. In addition, three recent researches have reported interesting results regarding cystatin C in kidney function 4,5,6. These had an impact on the 2012 Kidney Disease Improving Global Outcomes (KDIGO) guideline and led to its widespread clinical use.
Jeon et al. (Fri,) studied this question.